Dallas, TX (PRWEB) August 15, 2013
Key R&D trends in the Acute Myeloid Leukemia market include developing therapies for the patients with greatest unmet need, particularly the elderly, developing combination therapies, and investigating new targets (i.e. FLT3) involved in the pathogenesis of AML. Despite high levels of unmet need, uptake of new drugs will be limited, as KOLs are relatively unimpressed by these agents. Therefore, ample market opportunity will remain at the end of the forecast period. To circumvent historical difficulties with regulatory approval, companies are designing early- and late-stage clinical trials more rigorously. Randomization of early-stage trials is critical, and the designation of overall survival (OS) as the primary endpoint of pivotal studies is mandatory. Despite the hype around FLT3 inhibitors, KOLs are unconvinced that these drugs will be successful as monotherapies in AML.
This new research report published in Aug 2013, “OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017” ( http://www.reportsnreports.com/reports/267301-opportunityanalyzer-acute-myeloid-leukemia-aml-opportunity-analysis-and-forecasts-to-2017.html ), focuses on the remaining opportunity in AML exclusive of the acute promyleocytic leukemia (APL) subtype. The scope of this research includes: Overview of AML, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management; Topline AML therapeutics market revenue from 2012–2017. Annual cost of therapy, and peak pipeline drug sales of drugs launching during this forecast period are included; Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the AML therapeutics market; Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline drugs. An interactive clinical and commercial analyzer tool is available and an analysis of the current and future market competition in the global AML therapeutics market along with insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Buy a copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=267301 .
Key questions that this report will help you answer:
Comprehensive Table of Contents with 59 data Tables and 17 Figures for the report “OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017” can be accessed at http://www.reportsnreports.com/reports/267301-opportunityanalyzer-acute-myeloid-leukemia-aml-opportunity-analysis-and-forecasts-to-2017.html .
Explore more reports on the Pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ and on the Healthcare industry @ http://www.reportsnreports.com/market-research/healthcare/ .
ReportsnReports.com is an online market research reports library of 350,000+ in-depth studies of over 5000 micro markets. We provide 24/7 online and offline support service to our customers.
Read the full story at http://www.prweb.com/releases/acute-myeloid-leukemia/2017-forecasts-research/prweb11026098.htm.
Copyright©2012 Vocus, Inc.
All rights reserved